Tag: nasdaq:atrs

March 3, 2020

Antares Pharma Reports Q4 and Full Year 2019 Financial Results

Antares Pharma reported operating and financial results for the fourth quarter and full year ended December 31, 2019.
January 27, 2020

Antares Announces 2020 Revenue Guidance Range of up to US$155 Million

Antares announced its 2020 net revenue guidance of US$135 to US$155 million, which includes potential revenue scenarios for AMAG’s Makena.
November 28, 2018

Antares’ Device Aids Teva’s Generic EpiPen Launch

The EpiPen and this generic equivalent are indicated for the emergency treatment of severe allergic reactions.
November 27, 2018

Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen

Antares Pharma (NASDAQ:ATRS) announced that Teva Pharmaceutical Industries generic EpiPen is now commercially available in limited quantities. As quoted in the...
October 1, 2018

Antares Receives FDA Approval of Xyosted (Testosterone Enanthate) Injection for Testosterone Replacement Therapy

Antares Pharma (NASDAQ:ATRS) today announced the approval of XYOSTED (testosterone enanthate) injection by the U.S. Food and Drug Administration (FDA)....
August 17, 2018

Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector

Antares Pharma (NASDAQ:ATRS) announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical, epinephrine auto injector drug-device...